Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.55 |
| ▸ | MAPT | P10636 | 7/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3585588 | 0.87 | NPSR1 (0.54) | NPSR1ALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL3576658 | 0.86 | NPSR1 (0.55) | NPSR1ALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL3586151 | 0.80 | NPSR1 (0.50) | NPSR1ALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL3593253 | 0.79 | NPSR1 (0.59) | NPSR1ALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL3589035 | 0.77 | NPSR1 (0.67) | NPSR1ALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL3591427 | 0.77 | NPSR1 (0.49) | NPSR1ALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL3597401 | 0.76 | NPSR1 (0.55) | NPSR1ALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL3584369 | 0.76 | MAPT (0.59) | NPSR1ALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL3588494 | 0.76 | NPSR1 (0.52) | NPSR1ALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL13436124 | 0.75 | NPSR1 (0.77) | NPSR1ALDH1A1MAPTKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063065-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LIMITED (GB) | 2010-03-11 | — | — | US | claimed |
| EP-1937663-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | Inpharmatica Limited (GB) | 2008-07-02 | — | — | EP | claimed |
| WO-2007036730-A9 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LTD (GB) | 2008-06-19 | — | — | WO | claimed |
| WO-2007036730-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LIMITED (GB) | 2007-04-05 | — | — | WO | claimed |
| US-20100063065-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| US-20100063065-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| US-20100063065-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| EP-1937663-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | Inpharmatica Limited (GB) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007036730-A9 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LTD (GB) | 2008-06-19 | — | — | WO | disclosed |
| WO-2007036730-A9 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LTD (GB) | 2008-06-19 | — | — | WO | disclosed |
| WO-2007036730-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007036730-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063065-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | PPARG, PPARD, PPARA | NPSR1 706/4885ALDH1A1 1049/4885MAPT 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.